US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.34

-0.7701-1.79%

Post-market: 42.340.00000.00%16:10 EDT

Volume:2K

Turnover:64.58K

Market Cap:31.75M

PE:- -

High:42.35

Open:42.35

Low:42.34

Close:43.11

52wk High:43.11

52wk Low:29.32

Shares:750.00K

Float Shares:750.00K

Volume Ratio:2.57

T/O Rate:0.20%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units

Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club

Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)

Simply Wall St.

Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2

Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)

Stanley Druckenmiller Ditched These Chip Plays Before the Selloff. Here's How He's Playing the Tech Sector Now.

Natera Co-Founder, Director Sheena Jonathan Sells 6,000 Shares Worth $1.95 Million

Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

MT Newswires Live

Natera (NTRA) Gets a Buy from Citi

Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400

THOMSON REUTERS

Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million

Natera, Inc. : Citigroup Raises Target Price to $365 from $315

THOMSON REUTERS

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000

Natera, Inc. : Stephens Raises Target Price to $350 from $305

THOMSON REUTERS

Natera Partners with Kupando Therapeutics to Use Latitude ctDNA Test in Phase 1 Skin Cancer Trial

Natera to Support New Clinical Trial Assessing Ctdna Dynamics with Latitude™ in Advanced Skin Cancers

THOMSON REUTERS

Natera, Inc. : Piper Sandler Raises Target Price to $363.50 from $249

THOMSON REUTERS

China's Green Fuel Sector Shifts from Pilot Projects to Mass Production

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/HELX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.3399,"timestamp":1787601600000,"preClose":43.11,"halted":0,"volume":1524,"hourTrading":{"tag":"盘后","latestPrice":42.3399,"preClose":42.3399,"latestTime":"16:10 EDT","volume":10,"amount":423.399,"timestamp":1787602205265,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01786360473208071,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":-0.7701,"latestTime":"08-24 17:24:33 EDT","open":42.35,"high":42.35,"low":42.3399,"amount":64576,"amplitude":0.000234,"askPrice":63.76,"askSize":200,"bidPrice":21.26,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":43.11,"sharesOutstanding":650000,"nav":43.201,"aum":32400497.63,"dividendRate":0.003361,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.3399,"preClose":42.3399,"latestTime":"16:10 EDT","volume":10,"amount":423.399,"timestamp":1787602205265,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.565656,"impliedVol":0.2459,"impliedVolPercentile":0.8606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.565656,"shares":750000,"dividePrice":0.1423,"high":42.35,"amplitude":0.000234,"preClose":43.11,"low":42.3399,"week52Low":29.32,"pbRate":"--","week52High":43.11,"institutionHeld":0,"latestPrice":42.3399,"eps":0,"divideRate":0.003361,"volume":1524,"delay":0,"ttmEps":0,"open":42.35,"prevYearClose":36.3062,"prevWeekClose":43.11,"prevMonthClose":38.8312,"prevQuarterClose":39.9651,"fiveDayClose":41.1366,"twentyDayClose":38.8569,"sixtyDayClose":34.2035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660479247","title":"Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479247?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:29","pubTimestamp":1787182181,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals released an interim H1 2026 results presentation outlining...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","BK4585","MEDX","JDOC","GNMX","GDOC","WDNA","BMED","LFSC","HTEC","PBE","GNOM","TLX","BK4588","TMAT","XT","FDIF","BK4139","IBB","IDNA","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428271","title":"Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428271","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428271?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:22","pubTimestamp":1787142120,"startTime":"0","endTime":"0","summary":"Soccer-Sheffield United's ex-owners winds up company which bought clubLONDON, Aug 19 (Reuters)-Sheffield United's former owner on Wednesday won a bid to wind up the company that in 2024 bought the sec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL1N44F0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4585","LU0320765992.SGD","PTH","LU0109394709.USD","BK4551","GNOM","LFSC","GH","GNMX","LU0889565916.HKD","BK4588","EKG","FFOX","GDOC","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660341081","title":"Reaffirmed 2026 Guidance After Strong Q2 Could Be A Game Changer For Ligand Pharmaceuticals (LGND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660341081","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660341081?lang=en_us&edition=fundamental","pubTime":"2026-08-19 13:15","pubTimestamp":1787116520,"startTime":"0","endTime":"0","summary":"In August 2026, Ligand Pharmaceuticals reported past second-quarter 2026 results showing revenue of US$63.69 million and net income of US$48.51 million, with basic earnings per share from continuing operations of US$2.42, alongside stronger first-half results than the prior year. \nImportantly for longer-term watchers, Ligand also reaffirmed its 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/reaffirmed-2026-guidance-after-strong-q2-could-be-a-game-cha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals/news/reaffirmed-2026-guidance-after-strong-q2-could-be-a-game-cha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU0566484027.USD","IE0009354923.USD","LU1559883803.SGD","LGND","HELX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660970474","title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2660970474","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660970474?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:15","pubTimestamp":1787091347,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa disposes of 116 common shares worth $18,148.2Guardant Health director Tariq Musa sold 116 common shares on Aug. 17 at USD 156.45.The sale cut his directly held stak","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbdy8Tn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","GNOM","HELX","BK4535","LU0109394709.USD","BK4196","LFSC","PTH","EKG","GH","LU0320765992.SGD","LU0889565916.HKD","GNMX","GDOC","FFOX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660495332","title":"Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495332?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:26","pubTimestamp":1787059570,"startTime":"0","endTime":"0","summary":"Why Guardant Health Stock Is Back on Investors’ Radar\nGuardant Health (GH) moved into focus after several Q2 2026 developments, including FDA approval of an updated Guardant360 liquid biopsy test and new American Cancer Society support for its Shield colorectal cancer screening.\nThese clinical and guideline milestones arrived alongside stronger than expected Q1 results related to test volume and coverage trends. This provided investors with fresh information on how the company’s product...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","BK4535","LFSC","EKG","LU0109394709.USD","BK4551","FFOX","HELX","GH","PTH","BK4588","BK4585","GNOM","LU0889565916.HKD","GNMX","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436627","title":"Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660436627?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:20","pubTimestamp":1786980007,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Adagene (ADAG) and Natera (NTRA). Adagene (ADAG) M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adagene-adag-and-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-adagene-adag-and-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770993.USD","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","LU2264538146.SGD","LU0106261612.USD","BK4581","BK4139","LU0963586101.USD","LU0345770308.USD","HCSG","LU1988902786.USD","NTRA","LU0029874061.USD","BK4137","XLV","HELX","XBI","BK4585","LU0012050646.USD","LU0128526141.USD","LU2324357040.USD","LU2065731478.USD","BK4588","LU1064131342.USD","ADAG","LU0053671581.USD","LU2065171311.SGD","GNOM","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660802435","title":"Stanley Druckenmiller Ditched These Chip Plays Before the Selloff. Here's How He's Playing the Tech Sector Now.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660802435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660802435?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:29","pubTimestamp":1786976940,"startTime":"0","endTime":"0","summary":"Healthcare remains a top bet for the closely followed investorStanley Druckenmiller's Duquesne Family Office is leaning a little more into tech lately.Earlier this year, Stanley Druckenmiller spoke of","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1282649810.SGD","LU0289960550.SGD","IE0004086264.USD","LU1868837565.USD","LU2458330243.SGD","BK4543","LU1988902786.USD","LU2491049909.HKD","IE00B3M56506.USD","LU1989772923.USD","LU2663582299.SGD","LU0082616367.USD","BK4581","LU1211504680.USD","LU2065171402.SGD","LU2087625088.SGD","BK4533","EMC","LU0359201885.HKD","LU0878005551.USD","LU2023251221.USD","LU0348723411.USD","BK4503","CHPX","LU1852331112.SGD","LU2506951792.HKD","LU0211328371.USD","LU0072462343.USD","IE00BFXG0V08.USD","LU0541501648.USD","LU1868837722.USD","LU2089283258.USD","CGNG","LU1267930813.SGD","LU0965509283.SGD","LU2237443622.USD","LU1934455863.HKD","LU1917777945.USD","LU2491050154.USD","WUGI","AIQ","LU0965508806.USD","LU0175139822.USD","STM","LU2125154778.USD","LU0238689110.USD","EMM","UMMA","IE00BQXX3F31.USD","GNOM","LU0384037296.USD","LU2237443549.SGD","LU2054465674.USD","LU2028103732.USD","LU2211815571.USD","BK4554","LU0094547139.USD","ESIM","LU0792757196.USD","LU2065171311.SGD","BK4591","LU1037948541.HKD","LU0359202008.SGD","LU2491050071.SGD","CWI","LU0359201612.USD","LU0211327993.USD","SPWO","LU1508157978.USD","SGXZ51526630.SGD","BK4512","TSM","LU0198837287.USD","LU1037948897.HKD","LU2133065610.SGD","IE00BQXX3D17.EUR","LU2750360997.AUD","SG9999004220.SGD","AVSE","IE00BHPRN162.USD","IE0004091025.USD","LU0882747503.HKD","BK4585","LU1048588211.SGD","IE0004445239.USD","LU0345770308.USD","LU0823414478.USD","TSMY","BK4139","LU0124676726.USD","LU0158827948.USD","LU1712237335.SGD","LU1282649067.USD","03145","IE00BMPRXR70.SGD","LU0823421333.USD","BK4604","LU0323591593.USD","LU2065169927.USD","SGXZ99366536.SGD","LU1868838027.USD","LU0316494557.USD","LU2041044095.USD","LU2106854487.HKD","LU1989764664.SGD","LU2089284900.SGD","ADVE","LU2247934214.USD","LU2249611893.SGD","BK4548","LU0488056044.USD","LU1023057109.AUD","LU2471134879.HKD","BK4141","LU0143863784.USD","LU2125154935.USD","LU2360108059.USD","LU2063271972.USD","LU2458330169.SGD","LU0965509010.AUD","LU2264538146.SGD","TSMZ","LU1989764748.USD","LU2211814178.USD","LU2092937221.SGD","LU2750360641.GBP","BAI","MEMX","LU0109392836.USD","LU2298321311.HKD","IE00BQXX3C00.GBP","LU0878004406.USD","CGDG","LU0889565833.HKD","SG9999000418.SGD","IE00BYQQ9H92.USD","LU0143863198.USD","LU2471134952.CNY","BK4550","BLOX","CGIC","LU0823414551.USD","LU2471134796.USD","BK4526","STSM","LU0889566641.SGD","LU2023250504.SGD","LU2271345857.HKD","SMH","LU0861579265.USD","LU2324357040.USD","LU2860962120.EUR","BK4602","LU0310799852.SGD","IE00BZ199S13.USD","TSMG","CNEQ","LU2471134523.USD","LU1934455277.USD","TEK","LU1934455194.USD","CGGO","LU2360032135.SGD","TTEQ","BK4527","LU1803068979.SGD","LU0353189680.USD","SGXZ81514606.USD","LU1323610961.USD","LU0572940350.SGD","CORO","LU2065731478.USD","TSMX","LU0963586101.USD","ASIA","LU1064131342.USD","IE00BKPKM429.USD","HELX","LU0345770993.USD","LU0642271901.SGD","LU1267930490.SGD","IE00BMPRXN33.USD","LU2065170008.USD","LU2250418816.HKD","LU2294711713.HKD","LU0541502299.USD","KNOW","LU0353189763.USD","BK4505","LU0056508442.USD","SPTE","LU0006061336.USD","LU2357125470.USD","LU0106261612.USD","LU1974910355.USD","LU1989772840.SGD","TINS","LU2543165471.USD","NTRA","BK4534","TSMU","FDTX","LU0158827781.USD","AVEM","LU2111349929.HKD","IE00BD6J9T35.USD","LU0572939691.SGD","BK4532","BK4605","LU1623119135.USD","LU2237443382.USD","LU0823421416.USD","LU2360106780.USD","BK4588","LU0719512351.SGD","BK4612","LU1316542783.SGD","LU0012050646.USD","AVXC","LU0965509101.SGD","LU0264606111.USD","LU2237443978.SGD","IE00B5TLWC47.USD","LU0689626769.HKD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659812795","title":"Natera Co-Founder, Director Sheena Jonathan Sells 6,000 Shares Worth $1.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659812795","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659812795?lang=en_us&edition=fundamental","pubTime":"2026-08-15 09:35","pubTimestamp":1786757742,"startTime":"0","endTime":"0","summary":"Natera co-founder, Director Sheena Jonathan sells 6,000 shares worth $1.95 millionNatera director and co-founder Sheena Jonathan sold 6,000 common shares on Aug. 10, 2026 at USD 325.32 each.Directly h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260815:nNDL1dBDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Co-Founder, Director Sheena Jonathan Sells 6,000 Shares Worth $1.95 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","LU2264538146.SGD","LU0106261612.USD","GNOM","LU0963586101.USD","LU0345770308.USD","LU1988902786.USD","NTRA","LU0012050646.USD","LU2324357040.USD","LU2065731478.USD","LU1064131342.USD","LU0053671581.USD","LU2065171311.SGD","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659124086","title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124086?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:23","pubTimestamp":1786746202,"startTime":"0","endTime":"0","summary":"Krystal Biotech Director Dino A. Rossi disposes of USD 8.17 million in common sharesDirector Dino A. Rossi cut his Krystal Biotech stake to 50,000 shares on Aug. 14, 2026.Disposed of 25,000 common sha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6DCXXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4139","KRYS","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","KRYS","BK4581","BK4139","HELX","XBI","PSCH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659729143","title":"Natera (NTRA) Gets a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2659729143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659729143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:57","pubTimestamp":1786705032,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Natera, with a price target of $365.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-citi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-citi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","LU1064131342.USD","LU2065171402.SGD","LU0345770308.USD","LU2065731478.USD","LU0106261612.USD","LU0053671581.USD","LU0012050646.USD","LU2264538146.SGD","BK4139","LU0345770993.USD","LU2065171311.SGD","GNOM","LU1988902786.USD","LU0963586101.USD","NTRA","LU2324357040.USD","LU2065170008.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","PSCH","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659719596","title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659719596","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659719596?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:21","pubTimestamp":1786663307,"startTime":"0","endTime":"0","summary":"Guardant Health Chief People Officer Terilyn Monroe disposes of common shares worth $7.61 millionGuardant Health Chief People Officer Terilyn J. Monroe cut her direct common stock stake to 22,979 shar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1rsYJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4535","HELX","LU0889565916.HKD","GH","PTH","LFSC","GDOC","LU0320765992.SGD","BK4551","BK4588","GNMX","GNOM","BK4585","EKG","FFOX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659153712","title":"Natera, Inc. : Citigroup Raises Target Price to $365 from $315","url":"https://stock-news.laohu8.com/highlight/detail?id=2659153712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659153712?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:33","pubTimestamp":1786617184,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171311.SGD","LU2264538146.SGD","LU2065171402.SGD","HELX","LU0345770993.USD","LU0053671581.USD","LU0963586101.USD","LU0106261612.USD","LU0345770308.USD","NTRA","LU1064131342.USD","LU1988902786.USD","BK4139","GNOM","LU2065169927.USD","LU2065170008.USD","LU2065731478.USD","LU0012050646.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189872","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189872","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189872?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:34","pubTimestamp":1786577651,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 3,000 shares for $75,000Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 3,000 common shares on Aug. 10","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6LzfyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658118976","title":"Natera, Inc. : Stephens Raises Target Price to $350 from $305","url":"https://stock-news.laohu8.com/highlight/detail?id=2658118976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658118976?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:21","pubTimestamp":1786530064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171402.SGD","HELX","LU2264538146.SGD","LU0963586101.USD","LU1064131342.USD","LU0053671581.USD","LU0345770308.USD","LU0012050646.USD","BK4139","NTRA","LU2324357040.USD","LU2065169927.USD","GNOM","LU2065731478.USD","LU2065171311.SGD","LU0106261612.USD","LU2065170008.USD","LU0345770993.USD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975282","title":"Natera Partners with Kupando Therapeutics to Use Latitude ctDNA Test in Phase 1 Skin Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975282","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975282?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:01","pubTimestamp":1786528893,"startTime":"0","endTime":"0","summary":"Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trialNatera entered a collaboration with Kupando Therapeutics to support a Phase 1 trial of immunotherapy ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbT5KLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","NTRA","LU2065731478.USD","LU2065169927.USD","BK4139","LU0012050646.USD","LU0053671581.USD","LU1064131342.USD","LU2264538146.SGD","LU2065171311.SGD","LU0345770308.USD","LU0345770993.USD","HELX","LU1988902786.USD","LU2324357040.USD","LU0106261612.USD","GNOM","LU2065170008.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975416","title":"Natera to Support New Clinical Trial Assessing Ctdna Dynamics with Latitude™ in Advanced Skin Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975416?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:00","pubTimestamp":1786528800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA74PDL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0963586101.USD","BK4139","LU0106261612.USD","LU0012050646.USD","LU0053671581.USD","LU0345770308.USD","LU2065171311.SGD","GNOM","LU1064131342.USD","LU2065171402.SGD","LU2324357040.USD","NTRA","LU1988902786.USD","LU2065731478.USD","LU0345770993.USD","LU2065169927.USD","HELX","LU2065170008.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975588","title":"Natera, Inc. : Piper Sandler Raises Target Price to $363.50 from $249","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975588?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:49","pubTimestamp":1786528145,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU0053671581.USD","LU0345770308.USD","LU2065170008.USD","LU0963586101.USD","LU1988902786.USD","LU0345770993.USD","LU0012050646.USD","LU2065169927.USD","LU2264538146.SGD","LU2065171402.SGD","LU0106261612.USD","HELX","NTRA","LU2065731478.USD","BK4139","GNOM","LU2065171311.SGD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109741990","title":"China's Green Fuel Sector Shifts from Pilot Projects to Mass Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1109741990","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109741990?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:20","pubTimestamp":1786504847,"startTime":"0","endTime":"0","summary":" As global climate governance enters a critical phase, green fuel, a key link between renewable energy and end-use consumption, is transitioning from an \"option\" to a \"necessity.\" Li Zhongwu,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}